Căutați rapid medicamente. Încercați funcția de verificare a interacțiunilor.
Căutați rapid medicamente. Încercați funcția de verificare a interacțiunilor.
Geneva Score for VTE Prophylaxis

Geneva Score for VTE Prophylaxis

Identification of acutely ill medical patients requiring thromboprophylaxis

Low risk
VTE prophylaxis generally not recommended
0

General information

Age > 60 years
Pregnancy
Obesity
BMI > 30 kg/m²
BMI calculator
BMI: body mass index

Current conditions

Cardiac failure
Respiratory failure
Acute infection/sepsis
Acute rheumatic disease
Active malignancy
Myeloproliferative syndrome
Nephrotic syndrome
Chronic venous insufficiency
Dehydration
Subjective assessment
Immobilization for ≥ 3 days
Complete bed rest or inability to walk for > 30 min per day

History

Recent stroke
< 3 months ago
Recent myocardial infarction
< 4 weeks ago
History of VTE
Known thrombophilia
Recent travel for > 6 hrs
Hormonal therapy
Contraceptive or substitutive
VTE: venous thromboembolism

Informații suplimentare

Listați sau salvați ca PDF
Instrucțiuni și referințe

Avertizare

Acest instrument este destinat exclusiv scopurilor educaționale și nu constituie consultație de specialitate sau substitut pentru consultațiile de specialitate. Instrumentul nu trebuie folosit pentru diagnosticarea medicală și/sau acordarea tratamentului medical corespunzător.
General description
Venous thromboembolism (VTE) is one of the most common cardiovascular diseases and about 50% of all VTE events occur as a result of a hospital admission for surgery or acute medical illness. Hospital-acquired VTE is preventable, with interventions including anticoagulants and mechanical measures reducing the rate of symptomatic VTE by half.
Geneva Risk Score is one of the risk assessment models developed for identifying hospitalised medical patients at increased risk of VTE. It consists of 19 variables and a points-based system that enables stratification of patients into high and low VTE risk and can thus help inform decisions on prescription of thromboprophylaxis; however, decisions on thromboprophylactic interventions should also be based on assessment of bleeding risk.
Geneva Risk Score has been externally validated and compared favourably with the Padua Prediction Score, particularly for its accuracy in identifying low-risk patients who do not require thromboprophylaxis.

Result ranges

Low risk
VTE prophylaxis generally not recommended
0–3
High risk
VTE prophylaxis generally recommended
≥ 3

Formula

Cardiac failure, respiratory failure, recent stroke, recent myocardial infarction, acute infection/sepsis, acute rheumatic disease, active malignancy, myeloproliferative syndrome, nephrotic syndrome, history of VTE, known thrombophilia are assigned 2 points if they are answered yes. The rest are assigned 1 point if answered yes. All questions are assigned 0 points if answered no.

References

Chopard, P et al. “Identifying acutely ill medical patients requiring thromboprophylaxis.” Journal of thrombosis and haemostasis : JTH vol. 4,4 (2006): 915-6. doi:10.1111/j.1538-7836.2006.01818.x
Nendaz, M et al. “Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism. Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE).” Thrombosis and haemostasis vol. 111,3 (2014): 531-8. doi:10.1160/TH13-05-0427

Versiune

1

Despre acest instrument

Venous thromboembolism (VTE) is one of the most common cardiovascular diseases and about 50% of all VTE events occur as a result of a hospital admission for surgery or acute medical illness. Hospital-acquired VTE is preventable, with interventions including anticoagulants and mechanical measures reducing the rate of symptomatic VTE by half.
Geneva Risk Score is one of the risk assessment models developed for identifying hospitalised medical patients at increased risk of VTE. It consists of 19 variables and a points-based system that enables stratification of patients into high and low VTE risk and can thus help inform decisions on prescription of thromboprophylaxis; however, decisions on thromboprophylactic interventions should also be based on assessment of bleeding risk.
Geneva Risk Score has been externally validated and compared favourably with the Padua Prediction Score, particularly for its accuracy in identifying low-risk patients who do not require thromboprophylaxis.
Drugs app phone

Utilizați aplicația Mediately

Obțineți mai rapid informații despre medicamente.

Scanați cu camera telefonului.
4.9

Peste 36k recenzii

Utilizați aplicația Mediately

Obțineți mai rapid informații despre medicamente.

4.9

Peste 36k recenzii

Instalați

Depășește informațiile despre medicamente cu PRO

Rezolvați interacțiunile, vizualizați restricțiile de utilizare și găsiți toate celelalte răspunsuri cu asistentul dvs. AI Elly.

Preveri, kaj ponuja PRO
Utilizăm cookie-uri Cookie-urile ne ajută să oferim cea mai bună experiență pe site-ul nostru. Utilizând site-ul nostru, sunteți de acord cu utilizarea cookie-urilor. Aflați mai multe despre modul în care folosim cookie-urile în Politica noastră privind cookie-urile.